PFIZER REPORTS THIRD-QUARTER 2017 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pfizer (PFE) Tops Q3 EPS by 2c, Lifts FY EPS Guidance
October 31, 2017 6:46 AM EDT(Updated - October 31, 2017 6:49 AM EDT)
Pfizer (NYSE: PFE) reported Q3 EPS of $0.67, $0.02 better than the analyst estimate of $0.65. Revenue for the quarter came in at $13.17 billion versus the consensus estimate of $13.17 billion.
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, We reported solid third-quarter 2017 financial results and raised the midpoint of the range for our 2017 Adjusted diluted EPS(2) guidance.... More
